Skip to content

CELforPharma

Active Private limited companyfounded 2005active for 21 yearsJan Mommaertslaan 20, 1831 Machelen (Brab.)KBO/BCE: BE 0871.088.704 subsidiary of LAICO4Growth
CELforPharma
Follow ReportCompare

Overview

Lifetime

20 annual accounts with figures on one time axis, 21 filings since 2005
peak €1.1m (2021)
€149,685▼ 36.0%
lowest -€47,598 (2023)
-€21,251▼ €58,842
peak €844,024 (2019)
€323,248▼ 6.2%
€296,699▲ 28.4%
peak 7.4 FTE (2021)
2 FTE▼ 20.0%
Board4 names since 2021
1 directorLAICO4Growth BV
Owners
100%LAICO4Growth
Documentsfilings and deeds
03-06-202658 days before the deadline
2025abbreviated format
Gross margin from €233,885 to €149,685Loss of €21,251Staff from 2.5 FTE to 2 FTEPermanent representatives: Luc De Langhe and Annelies Swaan 09-07Debts from €231,119 to €296,699Cash from €132,932 to €191,285

Key points

from the 2025 annual accounts

Equity

€323,248 from €844,024 in 2019

Equity fell by 62% in 6 years.

Result

-€21,251 -€21,251
€37,6002024-€21,3002025

From profit to loss in 2025, after a profit of €37,590 in 2024.

Turnover

≈ €240,000 estimated

The abbreviated format states no turnover.

Staff

2 FTE from 7.4 in 2021

Between 2021 and 2025, 73% of the full-time equivalents disappeared.

Filings

21 annual accounts since 2005
AprilJune31 JulyOctober20052010201520202025

The 2019 accounts came 27 days late. The other nine of the last ten were filed on time.

Position in the sector

-€21,251

Lower net result than 88% of companies in head offices and management consultancy. Sector median €37,500 · 10,856 companies.

Checked score

93
Excellent
Financially stronger than 43% of micro companies in head offices and management consultancy (NACE 70)
Probability in this band: under 0.55%
Bankruptcy probability within 12 months
< 0.1% Very low
0%0.5%1.5%4%10%≥ 25%

The dashed line is the sector median: 0.1% across 48,570 companies (NACE 70, micro).

Fewer than 1 in 1,000 comparable companies go bankrupt within 12 months (an estimate).

Last 24 months 12-2024: 0.1% 01-2025: 0.1%● unchanged vs 12-2024 02-2025: 0.1%● unchanged vs 01-2025 03-2025: 0.1%● unchanged vs 02-2025 04-2025: 0.1%● unchanged vs 03-2025 05-2025: 0.1%● unchanged vs 04-2025 06-2025: 0.1%● unchanged vs 05-2025highest value 07-2025: < 0.1%▼ -0.1 percentage points vs 06-2025 08-2025: < 0.1%● unchanged vs 07-2025 09-2025: < 0.1%● unchanged vs 08-2025 10-2025: < 0.1%● unchanged vs 09-2025 11-2025: < 0.1%● unchanged vs 10-2025 12-2025: < 0.1%● unchanged vs 11-2025 01-2026: < 0.1%● unchanged vs 12-2025 02-2026: < 0.1%● unchanged vs 01-2026 03-2026: < 0.1%● unchanged vs 02-2026lowest value 04-2026: < 0.1%● unchanged vs 03-2026 05-2026: < 0.1%● unchanged vs 04-2026 06-2026: < 0.1%● unchanged vs 05-2026 07-2026: < 0.1%● unchanged vs 06-2026 08-2026: < 0.1%● unchanged vs 07-2026 09-2026: < 0.1%● unchanged vs 08-2026 10-2026: < 0.1%● unchanged vs 09-2026 11-2026: < 0.1%● unchanged vs 10-2026

Financial strength
Strong

77-8equity 52.1% of total assets
86+9short-term debt 13.5% · cash 30.9%
21-51return on assets -3.4%

Score breakdown

raises risk
Loss of €21,251 (financial year 2025)
lowers risk
Liquidity: current ratio 6.86, cash €191,285
Equity €323,248 (52.1% of total assets)
Sector: Activities of head offices; management consultancy activities (NACE 70)
Calculation

The band follows from the bankruptcy probability. 10 more points roughly halve it.

75-100 Excellent under 0.55%
60-74 Healthy 0.55% to 1.5%
45-59 Fair 1.5% to 4.2%
25-44 Weak 4.2% to 15.0%
0-24 Critical over 15.0%

Where the company stands within its band depends half on the bankruptcy probability and half on how it does against its sector peers (NACE 70, micro). It does better than 48% of them on solvency, 79% on liquidity, 14% on profitability and 31% on growth.

The bankruptcy probability was computed on 09-11-2026 by the bankruptcy model of 2 October 2026, which learns from Belgian bankruptcies and reads the registers, the annual accounts and the Belgian Official Gazette.

The probability rests on the annual accounts with balance sheet date 31-12-2025.

Of the companies with a bankruptcy probability in the very low class on 30-06-2025, 0.1% went bankrupt within twelve months.

Some facts cap the score, however low the probability. With negative or zero equity, a heavy loss, a special status in the KBO, one missing filing or accounts filed more than 90 days late, the score is Fair at most (59). With two missing filings, it is Weak at most (44). During a judicial reorganisation or at the company's end (bankruptcy, dissolution, liquidation), it is Critical at most (24).

Comparable companies, two years later

In July 2024, 12,322 companies had the same profile as CELforPharma has now. Each dot stands for 31 companies, two years later.

90.3%
were still trading
8.6%
stopped another way
0.7%
went bankrupt
  • Micro
  • 20 years or older
  • solvency 30% or more
  • a small loss

Another 0.5% stopped without a precise date, possibly only after those two years.

That fits the bankruptcy probability of CELforPharma itself: < 0.1% within 12 months.

Test of the method

The method was tested on the 497,447 companies of July 2024. Each company was given the bankruptcy share of the same profile a year earlier, in July 2023. The expectation was that 1.6% would go bankrupt within 24 months. In fact 1.7% went bankrupt.

The companies in ten equal groups, from the lowest to the highest expected share
Group Expected Actual
1 0.2% 0.2%
2 0.3% 0.5%
3 0.5% 0.6%
4 0.7% 0.8%
5 0.9% 0.9%
6 1.3% 1.5%
7 1.6% 1.8%
8 1.8% 1.8%
9 3.0% 3.1%
10 5.6% 6.2%

A company that went bankrupt had a higher expected share than one that kept going in 74.5% of comparisons. The level depends on the economy. In a year with more bankruptcies than the year before, the actual share is higher than the expected one.

This is an observation about 12,322 companies, not a prediction for CELforPharma. The sector does not count, because the KBO no longer lists a sector for a company that has stopped. By sector, mostly the survivors would count, which would paint too rosy a picture.

Credit verdict

Credit of up to €30,000 on 30-day terms is acceptable

Liquidity is ample, with a current ratio of 6.86 (7.01 in 2024), above the usual 1.5. Short-term debt is 13.5% and cash 30.9% of total assets. 47.9% of the assets are financed with debt and provisions.

Credit check for an amount and term of your choice

Show the recommended maximum and see how the verdict changes with amount, term and advance.

The scores and ratios are Checked's own calculations, not a credit decision.

Signals

Five signals.
lowers riskraises riskneutral
lowers risk · Liquidity: current ratio 6.86, cash €191,285
NBB · annual accounts
raises risk · Loss of €21,251 (financial year 2025)
NBB · annual accounts
lowers risk · Equity €323,248 (52.1% of total assets)
NBB · annual accounts
lowers risk · Sector: Activities of head offices; management consultancy activities (NACE 70)
KBO
neutral · Latest accounts filed on time
The financial year that closed on 31-12-2025 was due by 31-07-2026 and was filed on 03-06-2026, 58 days ahead of the deadline.
NBB · 10 filings
Deviation from the deadline
2025
58 days early
2024
49 days early
2023
56 days early
2022
53 days early
2021
11 days early
2020
57 days early
2019
27 days late
← before the deadline after the deadline →
tick = median of all Belgian filingsring = median in the sector

The company filed its last 7 accounts on average 37 days before the deadline. In the sector (NACE 70), the median for financial year 2024 was 9 days before the deadline, and 32% of those companies filed late.

Searched, nothing found (2)
neutral · Next filing not due yet
The next financial year closes on 31-12-2026 and is due by 31-07-2027. Nothing is late today. The company usually files around 8 June (4 of the last 5 accounts filed within 30 days either side of that date).
Companies Code · seven months
Where today falls in the filing period
09-11-2026 today31-12-2026 year end31-07-2027 deadline
neutral · No strike-offs in the KBO publications
That holds for every publication since 2021.
KBO publications

Board and ownership

LB
LAICO4Growth BV
Director
Board & ownership

Recent changes

Permanent representatives: Luc De Langhe and Annelies Swaan General meeting of 06-06-2025 · Gazette deed
Registered in the Peppol Directory Reachable for e-invoices through 0208:0871088704
New director LAICO4Growth appointed, Luc De Langhe resigned · Permanent representative: DE LANGHE Luc · General meeting of 14-02-2022 · Gazette deed
Incorporation published on 19-01-2005 · Gazette deed
All 33 events

Comparable companies

same main activity, similar in size and age
Company
CELforPharma Machelen (Brab.) €619,947 €149,685 52.1% 2
ADVANCED BUSINESS CONSULTING Orp-Jauche €538,290 €144,367 1.5% 1.7
FORESTCAPE Watermael-Boitsfort €652,339 €151,543 10.6% 1.7
Bloomz Diegem Machelen (Brab.) €561,275 €185,966 12.4% 1.8
P-MEDIA-GROUP Londerzeel €527,780 €169,438 29.7% 1.7
Workitects Leuven €803,520 €169,261 71.6% 2
WALLERS-ARENBERG Grimbergen €705,759 €131,748 38.3% 1

These companies have the same main activity as CELforPharma: business and other management consultancy (NACE 70200). They are comparable in size and age: total assets between €528,000 and €804,000, founded between 2002 and 2011.

Official details

Source: KBO
Status
Active since 07-01-2005Normal situation
Activity
Business and other management consultancyNACE 70200and 3 others
Joint committee
200Auxiliary committee for white-collar workers · annual accounts 2025
Establishment unit
2.145.692.1611831 Machelen (Brab.), since 07-01-2005
Financial year end
31 December
Peppol
Reachable since 10-01-2025
Company details

Annual accounts 2025

€149,685▼ 36.0%
€21,251
€323,248▼ 6.2%
€619,947▲ 7.7%
Employeeson 31-12-2025
2=
Filing
Filed on 03-06-2026, 58 days before the end of the filing period
Financials

Insights on CELforPharma

CELforPharma files the abbreviated format. That format states no turnover. The gross margin rose from €75,487 in 2006 to €149,685 in 2025.

LAICO4Growth holds all the shares.

Sources: KBO register, filings at the National Bank, Belgian Official Gazette.

Financials

Annual accounts 2025

abbreviated format, filed on 03-06-2026, 58 days before the deadline
€149,685
▼ 36.0%
-€10,011
▼ €53,361
-€21,251
▼ €58,842
€489,906
▲ 11.1%
52.1%
▼ 7.7 percentage points
6.86
▼ 0.14

Turnover and EBIT margin are not published. The abbreviated format does not require them. The turnover shown is an estimate from the gross margin.

Turnover ≈ €240,000. Estimated: probably between €190,000 and €310,000.

Balance sheet

balance sheet total €619,947 on 31-12-2025
What the company ownsHow it is paid for

in euro

in euro

Position in the sector

Compare with sector

52.1%

Higher than 50% of 10,856 companies in 2025.

6.86

Higher than 83% of 10,478 companies in 2025.

-3.4%

Higher than 12% of 10,725 companies in 2025.

CELforPharma Middle half of the sector 80% of the sector Abbreviated accounts in head offices and management consultancy (NACE 70)

Net result: bottom quarter · Equity: middle half · Balance sheet total: middle half · Working capital: top quarter · Staff: middle half

Staff

€66,855

Staff costs divided by the average number of full-time equivalents.

people who joined people who left

Filed annual accounts

as filed with the National Bank, click a year to choose it
Line Trend20252024202320222021202020192018201720162015201420132012201120102009200820072006
Balance sheet: assets
20/58 619,947575,619553,747698,777732,5561.1m1.3m1.2m1.1m782,380744,894684,461497,497349,162364,028263,693182,876175,587243,08692,660
21/28 46,51161,50178,06210,0536,55011,92811,43424,13336,12657,45273,25130,97424,7429,64010,8055,3072,8385,8848,2945,427
21 25,21436,99643,9186,6890491,31910,41719,51528,36931,314---------
22/27 21,29724,50534,1443,1645,9508,8707,10610,96113,85526,52639,78128,61822,3865,8166,9812,0835223,5685,9783,111
23 6,87212,22317,5741946311,2041,1812,4402,2869,22816,75512,0852,1115,8166,9812,0835223,5685,9783,111
24 6,1079,26112,6212,0542,8833394521,5293,0587,26811,4778,04310,724-------
26 8,3193,0213,9499162,4357,3275,4736,9928,51110,03011,5498,4909,551-------
28 --02006003,0093,0092,7562,7562,5562,1562,3562,3563,8243,8243,2242,3162,3162,3162,316
29/58 573,436514,117475,685688,724726,0071.1m1.3m1.1m1.0m724,928671,643653,488472,755339,522353,222258,386180,038169,703234,79387,232
29 ----032,84052,84064,84080,000-----------
291 ----032,84052,84064,84080,000-----------
40/41 104,681112,65269,100182,708262,806209,796177,240201,810137,862133,98379,319136,890114,94363,73848,25743,32518,42522,68599,6676,157
40 81,52284,57668,551143,568262,535156,561143,815154,026115,641133,98369,865132,924111,54462,16145,36638,1849,59717,48590,4465,869
41 23,15828,07655039,14027153,23533,42547,78422,221-9,4553,9663,3991,5772,8915,1418,8285,2009,221288
50/53 265,292262,953256,021250,820261,069263,804260,848256,068254,789253,627250,84599,000--------
54/58 191,285132,932144,941241,751188,223573,792755,919606,361533,924324,216329,200404,875346,836262,119282,351206,223155,762141,778132,77479,386
490/1 12,1795,5805,62413,44413,90910,90310,70114,46013,94513,10212,27912,72210,97613,66522,6158,8385,8525,2402,3521,689
Balance sheet: equity and liabilities
10/49 619,947575,619553,747698,777732,5561.1m1.3m1.2m1.1m782,380744,894684,461497,497349,162364,028263,693182,876175,587243,08692,660
10/15 323,248344,499306,909354,507353,031699,972844,024713,118655,246501,218418,832371,798210,380182,417179,262126,305120,56393,26667,66133,235
10/11 20,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,000
100 ------20,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,00020,000
13 303,248324,499286,909334,507333,031444,558588,610457,704399,832245,804163,418163,4182,0002,0002,0002,0002,0002,0002,0001,000
130/1 ---02,0002,000--------------
130 ------2,0002,0002,0002,0002,0002,0002,0002,0002,0002,0002,0002,0002,0001,000
1311 ---02,0002,000--------------
133 303,248324,499286,909334,507331,031442,558586,610455,704397,832243,804161,418161,418--------
14 --000235,414235,414235,414235,414235,414235,414188,380188,380160,417157,262104,30598,56371,26645,66112,235
17/49 296,699231,119246,838344,270379,526403,091424,960454,554401,400281,162326,062312,663287,117166,745184,765137,38762,31382,322175,42559,425
17 -------------------27,000
170/4 -------------------27,000
42/48 83,53073,353126,800110,866168,850209,720245,174367,952251,119225,532210,952164,578136,853124,503117,32590,93241,12127,02267,32530,025
44 57,45055,71071,81341,76934,86176,519115,306235,39972,896111,105129,20582,98256,58860,60562,96471,80126,92116,92344,07319,074
440/4 57,45055,71071,81341,76934,86176,519115,306235,39972,896111,105129,20582,98256,58860,60562,96471,80126,92116,92344,07319,074
46 1,0531,05315,410---------2,420-------
45 25,00516,56739,55439,074133,96677,973129,868132,417178,223114,42881,74780,90777,84562,64953,78418,81414,09710,09921,71510,502
450/3 6,7075,26622,65519,26980,43023,75845,85873,707128,50487,89648,58254,40555,30040,65432,9215,6472421,51120,9774,766
454/9 18,29811,30116,89919,80553,53654,21584,01058,70949,71926,53233,16526,50222,54521,99620,86313,16713,8568,5887385,735
47/48 24242430,0242455,228-136---689-1,248577317103-1,537449
492/3 213,169157,766120,038233,403210,675193,371179,78686,602150,28255,630115,110148,086150,26442,24267,44146,45521,19255,300108,1002,400
Income statement
76A 014,841------------------
9900 149,685233,885248,192322,5001.1m480,684844,827599,105646,739554,512468,227537,725315,261248,003271,053162,186167,580114,164141,25075,487
62 133,710166,056267,125244,087611,440428,051572,510458,264328,531362,891341,686228,741232,731226,687187,162146,108118,68468,62683,07044,866
630 21,85021,06111,1732,8262,9694,39913,92314,72623,62224,44922,72810,0938,0925,1764,0111,5633,0473,9744,3362,243
640/8 4,1373,4184,8933,4354,0591,0021,0029889751,1764485489,905927571348348348--
66A -0916----------1,031-----8
9901 -10,01143,350-35,91572,152469,59047,232257,392125,128293,612165,996103,365298,34464,53415,21379,30914,16745,50241,21653,84428,378
75/76B 4,7936,2374,7215,0386,3318,4827,12312,70317,1805,8469,4607,6718,1775,40117,2984,3202,4012,7441,8751,358
75 4,7936,2374,7215,0386,3318,4827,12312,70317,1805,8469,4607,6718,1775,40117,2984,3202,4012,7441,8751,358
65/66B 16,03311,99615,82234,64921,66819,35330,93620,46428,62214,05817,04119,56015,0087,88710,3626,4924,9932,5671,0892,180
65 16,03311,99615,82234,64921,66819,35330,93620,46428,62214,05817,04119,56015,0087,88710,3626,4924,9932,5671,0892,180
9903 -21,25137,590-47,01642,541454,25336,362233,580117,367282,170157,78395,783286,45457,70311,69586,24411,99542,91041,39254,63027,549
67/77 -058311,064123,22218,996102,67459,495128,14175,39748,750125,03729,7398,54133,2876,25315,61215,78820,20412,067
9904 -21,25137,590-47,59831,476331,03117,366130,90657,872154,02882,38647,033161,41827,9643,15452,9575,74227,29725,60434,42615,482
9905 -21,25137,590-47,59831,476331,03117,366130,90657,872154,02882,38647,033161,41827,9643,15452,9575,74227,29725,60434,42615,482
Appropriation of the result
9906 -21,25137,590-47,59831,476566,445252,780366,320293,286389,442317,800235,414349,798188,380160,417157,262104,30598,56371,26646,66113,235
14P ---0235,414---------------
791/2 21,251047,5980442,558161,418--------------
691/2 037,59001,476331,03117,366130,90657,872154,02882,386-161,418------1,0001,000
6920 ------------------1,0001,000
6921 037,59001,476331,03117,366130,90657,872154,02882,386-161,418--------
694/7 --030,000677,972161,418--------------
694 ---0677,972161,418--------------
695 --030,000----------------
Social balance sheet
9087 22.54.24.47.46.76.45.95.45.96.54.74.23.93.22.72.21.61.41
Hours worked1013 3,4564,1257,0706,84212,7299,03311,09510,3779,30810,3549,6097,0686,2926,2114,4584,2503,4442,6542,0901,702
Document PDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDFPDF

The accounts for financial year 2005 were filed as a document without figures as data, a scan for example.

The notes to these accounts have 11 items, including the statement of assets and debts, the cost breakdown and rights and commitments. You find them in the filed accounts (PDF).

Source: Annual accounts 2025 (PDF), filed on 03-06-2026.

Download as CSV

Filings

each dot is a set of accounts, on the day it reached the National Bank
Financial year Type Filed Reference Document
31-12-2025 abbreviated format 03-06-2026 2026-00133999 PDF
31-12-2024 abbreviated format 12-06-2025 2025-00133262 PDF
31-12-2023 abbreviated format 05-06-2024 2024-00109628 PDF
31-12-2022 abbreviated format 08-06-2023 2023-00112841 PDF
31-12-2021 abbreviated format 20-07-2022 2022-20202747 PDF
31-12-2020 abbreviated format 04-06-2021 2021-17500558 PDF
31-12-2019 abbreviated format 27-08-2020 2020-46100167 PDF
31-12-2018 abbreviated format 21-06-2019 2019-21300053 PDF
31-12-2017 abbreviated format 18-06-2018 2018-19700524 PDF
31-12-2016 abbreviated format 08-06-2017 2017-16100587 PDF
31-12-2015 abbreviated format 14-06-2016 2016-17700042 PDF
31-12-2014 abbreviated format 22-06-2015 2015-22100425 PDF
31-12-2013 abbreviated format 27-05-2014 2014-13900424 PDF
31-12-2012 abbreviated format 05-07-2013 2013-27600109 PDF
31-12-2011 abbreviated format 25-06-2012 2012-21100147 PDF
31-12-2010 abbreviated format 15-06-2011 2011-17000462 PDF
31-12-2009 abbreviated format 11-06-2010 2010-16900533 PDF
31-12-2008 abbreviated format 28-05-2009 2009-17100118 PDF
31-12-2007 abbreviated format 13-06-2008 2008-22900074 PDF
31-12-2006 abbreviated format 05-07-2007 2007-35300390 PDF
31-12-2005 abbreviated format 06-06-2006 2006-18500289 PDF

Subsidies and aid

Flemish government 2022 to 2023, 2 entries, €731 awarded, €731 paid

Subsidie voor opleiding en advies voor kmo's en zelfstandigen (kmo-portefeuille)
€731
Year Entries AwardedPaid
2023 1 €287€287
2022 1 €444€444

Key figures and ratios

per financial year, computed from the annual accounts
Line Trend20252024202320222021202020192018201720162015201420132012201120102009200820072006
11,83964,411-24,74274,978472,56051,631271,315139,853317,233190,445126,093308,43672,62620,38983,32015,73048,54845,19058,18030,621
59958,651-36,42534,303334,00021,765144,82972,598177,650106,83569,762171,51036,0568,33156,9687,30530,34429,57938,76217,725
6,8604,50080,2976,730-2,4094,8931,2242,7332,2968,65065,20616,32526,5525,0429,5104,03201,5657,2021,945
58,353-12,008-96,81153,528-385,570-182,127149,55972,437209,707-4,983-75,67658,03984,717-20,23176,12850,46113,9839,00453,388-
489,906440,764348,885577,857557,156881,4151.0m775,587769,402499,396460,690488,910335,903215,020235,897167,453138,917142,681167,46857,208
52.1%59.8%55.4%50.7%48.2%63.5%66.5%61.1%62.0%64.1%56.2%54.3%42.3%52.2%49.2%47.9%65.9%53.1%27.8%35.9%
6.867.013.756.214.305.205.133.114.063.213.183.973.452.733.012.844.386.283.492.91
0.920.670.800.971.080.580.500.640.610.560.780.841.360.911.031.090.520.882.591.79
-6.6%10.9%-15.5%8.9%93.8%2.5%15.5%8.1%23.5%16.4%11.2%43.4%13.3%1.7%29.5%4.5%22.6%27.5%50.9%46.6%
-3.4%6.5%-8.6%4.5%45.2%1.6%10.3%5.0%14.6%10.5%6.3%23.6%5.6%0.9%14.5%2.2%14.9%14.6%14.2%16.7%
0.745.37-1.562.1621.81---------------

A Belgian filing has no cash-flow statement. Cash flow is therefore an approximation, derived from the income statement. Investment is the acquisitions in the notes and, without them, the balance-sheet move.

Social balance sheet

Item31-12-202531-12-202431-12-202331-12-202231-12-2021
Employees at the balance-sheet date22346
full-time22334
part-time00012
in full-time equivalents2233.85.3
22.54.24.47.4
On a permanent contract22346
Joined-1213
Left-2335
Training hours--0--

Source: social balance sheet in the 2021 to 2025 annual accounts

Investments

fixed assets acquired
Item20252024202320222021
Tangible fixed assets€6,860-€39,087--
Intangible fixed assets-€4,500€41,210€6,730-
€21,850€21,061€11,173€2,826€2,969

Source: notes to the 2021 to 2025 annual accounts (statement of fixed assets)

Insights on CELforPharma

The operating result for 2025 is a loss of €10,011, after a profit of €43,350 in 2024.

Debt's share of the balance-sheet total rises from 40.2% to 47.9%. Equity is lower and debt is higher.

Board & ownership

Board

1 director, last change in 2022
LAICO4Growth BV
Director
listed in the 2025 annual accounts, filed on 03-06-2026
Signing authorityThe articles say who may bind the company, for example by signing a contract.
Each director alone
deed of 18-02-2022

Office holders in the KBO →

Mandates through the years

4 names, the dashed line is today
LAICO4Growth BV
Director
LAICO4Growth
Director (not named in the articles)
LAICO4Growth
Director (not named in the articles)
Luc De Langhe
Sole director (not named in the articles)
BoardEarliermandate already running before its first mentionend not dated
Mandates as a list
  • LAICO4Growth BV
    • Director, since before 31-12-2025
  • LAICO4Growth
    • Director (not named in the articles), from before 31-12-2021, no longer listed in the 2025 annual accounts
  • LAICO4Growth
    • Director (not named in the articles), appointed by deed of 18-02-2022, no longer listed in the 2025 annual accounts
  • Luc De Langhe
    • Sole director (not named in the articles), from before 31-12-2021 to 18-02-2022

See the board, name and registered office on a given date →

Control

Parent
LAICO4Growth
Equity €919,578
Profit €128,731 in 2026 (profit €121,328 in 2025)
Source: accounts LAICO4Growth 31-03-2026
100%
This company
CELforPharma
Equity €323,248
Loss €21,251 in 2025

Capital

Contribution
€20,000
Source
2025 annual accounts

Owners through the years

as the annual accounts name them
LAICO4Growth
100%
100%
Owners as a list

Source: lists of holdings in the owners' accounts

Articles of association

deed of 18-02-2022 (in Dutch)
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
Board ruleThese rules set how the board is made up, meets and takes decisions.
At least 1 director
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Fourth Friday of May at 16:00

Network & group

Group

LAICO4Growth has 1 direct subsidiary (accounts to 31-03-2026), the bar shows equity in euros
ParentLAICO4Growth1 holding, 1 country accounts to 31-03-2026

Belgium 1 Equity Result

  • BE CELforPharma BV €323,248 result -€21,251

Source: list of holdings in the 31-03-2026 accounts of LAICO4Growth. Every holding stands with its own latest accounts.

At the same address

Jan Mommaertslaan 20, 1831 Machelen · 7 other companies
AXON LAB
establishment since 01-04-2014 · founded in 2014
 13 FTE (2025)
0546.789.493
VOCALCOM
registered office since 24-02-1982 · founded in 1982 · negative equity (2025)
 5 FTE (2025)
0422.504.680
CrediBill
registered office since 19-01-2009 · founded in 2009
 1.3 FTE (2025)
0809.178.750
The Captains
registered office since 14-02-2020 · founded in 2020
 total assets €209,097 (2025)
0743.651.983
Lincoln Transition Executive
registered office since 17-06-2014 · founded in 2014 · negative equity (2025)
 1.2 FTE (2025)
0553.872.869
SOLIS ENERGY
registered office since 26-09-2023 · founded in 2023 · negative equity (2025)
 total assets €879 (2025)
1000.338.432
VITIS LIFE SA
establishment since 11-12-2017
 founded in 1995
0686.903.619

Connections & network

1 current director
Depth

The network starts from the directors of CELforPharma. Every other company they run is a node.

This company Company Director Shareholding +N: links not shown yet Click a node to look further, drag to arrange, zoom with the mouse wheel.

Timeline

Timeline

33 events since 2005

Deadline for the 2026 accounts: 31-07-2027

2026
Annual accounts 2025 filed PDFabbreviated format · 58 days before the deadline
2025
Permanent representatives: Luc De Langhe and Annelies SwaanGeneral meeting of 06-06-20253 points ▸
  • General meeting, 06-06-2025
  • Permanent representative, Luc De Langhe
  • Permanent representative, Annelies Swaan

Open the deed in the Belgian Official Gazette

Annual accounts 2024 filed PDFabbreviated format · 49 days before the deadline
Registered in the Peppol Directory Reachable for e-invoices through 0208:0871088704
2024
Back to profit net €37,590 The net result is €37,590, after one loss-making year.
Annual accounts 2023 filed PDFabbreviated format · 56 days before the deadline
2023
Weakest financial year net -€47,598 The net result drops to -€47,598, the lowest from 2006 to 2025. It recovers the following year.
Annual accounts 2022 filed PDFabbreviated format · 53 days before the deadline
2022
Annual accounts 2021 filed PDFabbreviated format · 11 days before the deadline
New directorLAICO4Growth appointed, Luc De Langhe resigned · Permanent representative: DE LANGHE Luc · General meeting of 14-02-20227 points ▸
  • General meeting, 14-02-2022
  • Director resignation, Luc De Langhe (sole director (not named in the articles))
  • Permanent representative, DE LANGHE Luc, mentioned twice in the deed
  • Director appointment, LAICO4Growth (director (not named in the articles))
  • 200 shares
  • Registered office clause, Jan Emiel Mommaertslaan 20A, 1831 Diegem
  • Power of attorney, Hugo VAN ELSLANDE
  • The deed holds 5 more points.

Open the deed in the Belgian Official Gazette

2021
Highest result from 2006 to 2025 net €331,031 ▲1,806% The operating result of €469,590 and the net result of €331,031 are both a record.
Annual accounts 2020 filed PDFabbreviated format · 57 days before the deadline
2020
Annual accounts 2019 filed PDFabbreviated format · 27 days late
2019
Annual accounts 2018 filed PDFabbreviated format · 40 days before the deadline
2018
Annual accounts 2017 filed PDFabbreviated format · 43 days before the deadline
2017
Annual accounts 2016 filed PDFabbreviated format · 53 days before the deadline
2016
Equity above €500,000 equity €501,218 ▲19.7% With a profit in every financial year since 2006, equity grows to €501,218.
Annual accounts 2015 filed PDFabbreviated format · 47 days before the deadline
2015
Annual accounts 2014 filed PDFabbreviated format · 39 days before the deadline
2014
Annual accounts 2013 filed PDFabbreviated format · 65 days before the deadline
2013
Equity above €200,000 equity €210,380 ▲15.3% With a profit in every financial year since 2006, equity grows to €210,380.
Annual accounts 2012 filed PDFabbreviated format · 26 days before the deadline
2012
Annual accounts 2011 filed PDFabbreviated format · 36 days before the deadline
2011
Equity above €150,000 equity €179,262 ▲41.9% With a profit in every financial year since 2006, equity grows to €179,262.
Annual accounts 2010 filed PDFabbreviated format · 46 days before the deadline
2010
Annual accounts 2009 filed PDFabbreviated format · 50 days before the deadline
2009
Equity above €100,000 equity €120,563 ▲29.3% With a profit in every financial year since 2006, equity grows to €120,563.
Annual accounts 2008 filed PDFabbreviated format · 64 days before the deadline
2008
Annual accounts 2007 filed PDFabbreviated format · 48 days before the deadline
2007
Annual accounts 2006 filed PDFabbreviated format · 26 days before the deadline
2006
Annual accounts 2005 filed PDFabbreviated format
2005
Incorporation PDFpublished on 19-01-2005
First establishment Jan Mommaertslaan 20a, Machelen (Brab.)

Financial milestones sit on the financial year-end date, not the filing date.

Sources: Publications in the Belgian Official GazetteFilings with the National Bank

History

CELforPharma was incorporated on 7 January 2005.1 In 2022 the company took the name CELforPharma.2 Total assets fell from €1.2m in 2018 to €619,947 in 2025 and headcount from 5.9 to 2 full-time equivalents.3

  1. 1KBO register
  2. 2Belgian Official Gazette, 18-02-2022
  3. 3National Bank, annual accounts 2018 and 2025

Company details

Identity

Enterprise number
0871.088.704
VAT number
BE 0871.088.704
Peppol ID
0208:0871088704
Other Peppol ID
9925:BE0871088704
Legal form
Private limited company
Status
Active, normal situation
Founded
07-01-2005
Financial year
ends on 31 December
Annual meetingThe shareholders approve the annual accounts, among other things, at the annual meeting.
Fourth Friday of May at 16:00
deed of 18-02-2022 (in Dutch)
Peppol
Reachable since 10-01-2025Follow this company and you will hear the next morning if it leaves the Peppol register.
Name
CELforPharma in Dutch
Entity type
Legal entity
DurationMost companies exist for an unlimited period, until they are dissolved.
Unlimited
deed of 18-02-2022 (in Dutch)
Registered office clauseThe articles name the region of the registered office. The language of official documents depends on that region, among other things.
“Vlaams Gewest”
deed of 18-02-2022 (in Dutch)

Activities

NACEBEL 2025
VAT activities
70200 Business and other management consultancy main activity
58130 Publishing activities
78100 Employment placement agencies
82990 Other business support services
Social security (RSZ) activities
82990 Other business support services main activity
Joint committees annual accounts 2025
JC 200 Auxiliary committee for white-collar workers
Codes under NACEBEL 2008
VAT activities
70220 Business consulting main activity
58140 Publishing activities
78100 Employment placement agencies
82990 Other business support services
Social security (RSZ) activities
82990 Other business support services main activity
Codes under NACEBEL 2003
VAT activities
74142 main activity
22130
74501
74879
Social security (RSZ) activities
74879 main activity
PurposeThe purpose describes the activities the company may carry out under its articles.
“Het aanbieden van zakelijke diensten aan farmaceutische en aanverwante bedrijven over de gehele wereld met het oog op kennisoverdracht naar…”
4 activities
  1. Het aanbieden van zakelijke diensten aan farmaceutische en aanverwante bedrijven over de gehele wereld met het oog op kennisoverdracht naar het management toe.De taak van de vennootschap is het identificeren van de expertise-en kennisnoden van managers in de farmaceutische en aanverwante bedrijven,het identificeren van de specialisten die de nodige expertise terzake bezitten,of,indien nodig,het recruteren en opleiden van experten terzake,om de nodige expertise aan te reiken onder de vorm van workshops,seminaries,vormingssessies,conferenties,publicaties,elektronische communicatiemiddelen,adviesopdrachten,en elke andere vorm van kennisoverdracht
  2. Het nemen van participaties in andere ondernemingen
  3. Uitoefenen van mandaten van bestuurder in andere vennootschappen
  4. Deelnemen of samenwerken met bestaande of nog op te richten ondernemingen die een gelijkaardig of complementair voorwerp hebben
deed of 18-02-2022 (in Dutch)

Registered office and establishments

1 establishment
Establishment Since Unit number
Jan Mommaertslaan 20 registered office 1831 Machelen (Brab.)
Jan Mommaertslaan 20a 1831 Machelen (Brab.) 82990 Other business support services 07-01-2005 2.145.692.161

Buildings and parcels at the address

Ground area
1.5 ha
Buildings
1,329 m²
Volume, LiDAR
25,449 m³
Tallest building
26.4 m
Buildings to scale, each on its own parcel
1,329 m², 26.4 m 1,329 m², 26.4 m

Location

registered office establishment The establishment unit on the map
8 companies at this address See who is registered here

Parcels

Cadastral parcelArea Buildings Height / floors
23015B0161/00D0061.5 ha 2 · 1,329 m² 26.4 m · 7

We would like to set cookies. That happens only with your consent. What we measure